These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 22369928)

  • 1. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.
    Zhao Q; Parris AB; Howard EW; Zhao M; Ma Z; Guo Z; Xing Y; Yang X
    Sci Rep; 2017 Sep; 7(1):11306. PubMed ID: 28900173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
    Bello E; Colella G; Scarlato V; Oliva P; Berndt A; Valbusa G; Serra SC; D'Incalci M; Cavalletti E; Giavazzi R; Damia G; Camboni G
    Cancer Res; 2011 Feb; 71(4):1396-405. PubMed ID: 21212416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.
    Delpuech O; Rooney C; Mooney L; Baker D; Shaw R; Dymond M; Wang D; Zhang P; Cross S; Veldman-Jones M; Wilson J; Davies BR; Dry JR; Kilgour E; Smith PD
    Mol Cancer Ther; 2016 Nov; 15(11):2802-2813. PubMed ID: 27550940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models.
    Phanhthilath N; Hakim S; Su C; Liu A; Subramonian D; Lesperance J; Zage PE
    Invest New Drugs; 2020 Dec; 38(6):1677-1686. PubMed ID: 32436058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
    Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
    Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells.
    Na YR; Kim JY; Song CH; Kim M; Do YT; Vo TTL; Choi E; Ha E; Seo JH; Shin SJ
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y; Cho H; Hur W; Sim T
    Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photopreventive Effect and Mechanism of AZD4547 and Curcumin C3 Complex on UVB-Induced Epidermal Hyperplasia.
    Khandelwal AR; Rong X; Moore-Medlin T; Ekshyyan O; Abreo F; Gu X; Nathan CA
    Cancer Prev Res (Phila); 2016 Apr; 9(4):296-304. PubMed ID: 26862088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
    Perera TPS; Jovcheva E; Mevellec L; Vialard J; De Lange D; Verhulst T; Paulussen C; Van De Ven K; King P; Freyne E; Rees DC; Squires M; Saxty G; Page M; Murray CW; Gilissen R; Ward G; Thompson NT; Newell DR; Cheng N; Xie L; Yang J; Platero SJ; Karkera JD; Moy C; Angibaud P; Laquerre S; Lorenzi MV
    Mol Cancer Ther; 2017 Jun; 16(6):1010-1020. PubMed ID: 28341788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
    Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
    Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo.
    Dai MD; Wang YL; Fan J; Dai Y; Ji YC; Sun YM; Peng X; Li LL; Wang YM; Duan WH; Ding J; Ai J
    Acta Pharmacol Sin; 2021 Sep; 42(9):1498-1506. PubMed ID: 33288861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of fibroblast growth factor receptor with AZD4547 mitigates juvenile nasopharyngeal angiofibroma.
    Le T; New J; Jones JW; Usman S; Yalamanchali S; Tawfik O; Hoover L; Bruegger DE; Thomas SM
    Int Forum Allergy Rhinol; 2017 Oct; 7(10):973-979. PubMed ID: 28707818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.